Editorial: High-time chemotherapy or high time for low dose

Journal of Clinical Oncology

Volumn 18, Issue 16, 2000, Pages 2935-2937

  Kamen, B A ^a   Rubin, E ^a   Aisner, J ^a   Glatstein, E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTOKINE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PACLITAXEL; PREDNISONE; PROCARBAZINE; TAXANE DERIVATIVE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; DRUG INDUCED DISEASE; DRUG MEGADOSE; EDITORIAL; HODGKIN DISEASE; HUMAN; NEUROBLASTOMA; PRIORITY JOURNAL; TREATMENT PLANNING; CELL CYCLE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 0034243694     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.16.2935     Document Type: Editorial

References (23)

1. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma
2. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13 cis-retinoic acid
3. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
4. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide thiotepa and carboplatin
5. Chemotherapeutic drugs: More really is not better
6. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
7. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
8. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target angiogenesis in mice
9. Back to the basics: The importance of concentration x time in oncology
10. Shifting the cancer paradigm: Must we kill to cure?
11. Pharmacodynamics in cancer therapy
12. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules
13. Purine analog 6-methyl-mercaptopurine riboside inhibits early and late stages of the angiogenesis process
14. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low dose methotrexate
15. Modification of treatment schedules in the management of advanced mouse leukemia with amethopterin
16. Angiogenesis in neuroblastoma: Relationship to survival and other prognostic factors in a cohort of neuroblastoma patients
17. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia
18. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group phase III trial
19. Oral vs IV MTX: Another opinion
20. Etoposide: Twenty years later
21. Gene silencing as a threat to the success of gene therapy
22. Epigenetic gene silencing in cancer
23. Above all do no harm or make sure the result is worthy of the suffering